Adverse Events Associated With Antibiotics and Intravenous Therapies for Post-Lyme Disease Syndrome in a Commercially Insured Sample.

摘要: Background Non-guideline-endorsed posttreatment courses of antibiotics for post-Lyme disease syndrome (PLDS) have been linked to adverse patient outcomes, but these findings yet be validated in large systematic evaluations. Methods A retrospective cohort analysis medical and pharmacy claims derived from the Truven Health Market Scan Commercial Claims Encounters Database assessed 90-day incidence rates events (AEs) associated with PLDS treatment (PLDS-Tx). Patients were diagnosed ≥6 months after initial diagnosis standard antibiotic Lyme disease. Comparison cohorts included intravenous (IV) PLDS-Tx or without oral antibiotics; antibiotic-only PLDS-Tx; neither. Results Composite AE higher patients treated IV than not receiving either (18.7%, 16.8%, 13.4%, respectively; P = .019). Significant between-group differences noted electrolyte imbalance (4.0%, 1.5%, 0.7%, .001) infection (14.0%, 12.7%, 9.3%; .006). Infection prevalence increased by 22.0% group 17.7% group. Incidence all-cause AE-related hospital stays emergency department visits nontreated patients, particularly when was (all < .01). Of IV-treated 7.3% experienced an incident inpatient stay 11.3% visit, compared with, respectively, 2.2% 3.4% those 0.9% 1.9% patients. Conclusions Use therapies morbidity within 90 days.